SG10201913075RA - Methods of treating cancer with anti-pd-1 antibodies - Google Patents
Methods of treating cancer with anti-pd-1 antibodiesInfo
- Publication number
- SG10201913075RA SG10201913075RA SG10201913075RA SG10201913075RA SG10201913075RA SG 10201913075R A SG10201913075R A SG 10201913075RA SG 10201913075R A SG10201913075R A SG 10201913075RA SG 10201913075R A SG10201913075R A SG 10201913075RA SG 10201913075R A SG10201913075R A SG 10201913075RA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- methods
- treating cancer
- cancer
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444336P | 2017-01-09 | 2017-01-09 | |
| US201762477423P | 2017-03-27 | 2017-03-27 | |
| US201762491220P | 2017-04-27 | 2017-04-27 | |
| US201762556386P | 2017-09-09 | 2017-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201913075RA true SG10201913075RA (en) | 2020-02-27 |
Family
ID=61188903
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906192SA SG11201906192SA (en) | 2017-01-09 | 2018-01-09 | Methods of treating cancer with anti-pd-1 antibodies |
| SG10201913075RA SG10201913075RA (en) | 2017-01-09 | 2018-01-09 | Methods of treating cancer with anti-pd-1 antibodies |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906192SA SG11201906192SA (en) | 2017-01-09 | 2018-01-09 | Methods of treating cancer with anti-pd-1 antibodies |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11407830B2 (fr) |
| EP (2) | EP3565844B8 (fr) |
| JP (2) | JP7110206B6 (fr) |
| KR (1) | KR102606252B1 (fr) |
| CN (1) | CN110382545A (fr) |
| AU (1) | AU2018206481A1 (fr) |
| BR (1) | BR112019014187A2 (fr) |
| CA (1) | CA3049440A1 (fr) |
| DK (1) | DK3565844T3 (fr) |
| ES (1) | ES2945745T3 (fr) |
| FI (1) | FI3565844T3 (fr) |
| HU (1) | HUE061842T2 (fr) |
| IL (1) | IL267804A (fr) |
| MA (1) | MA47208A (fr) |
| MX (1) | MX2019008207A (fr) |
| PL (1) | PL3565844T3 (fr) |
| PT (1) | PT3565844T (fr) |
| SG (2) | SG11201906192SA (fr) |
| TW (1) | TWI767976B (fr) |
| WO (1) | WO2018129559A1 (fr) |
| ZA (1) | ZA201904316B (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX364200B (es) | 2008-04-09 | 2019-04-16 | Genentech Inc | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. |
| CN117586403A (zh) | 2016-10-11 | 2024-02-23 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
| AU2017354070A1 (en) * | 2016-11-01 | 2019-05-16 | Anaptysbio, Inc. | Antibodies directed against programmed death- 1 (PD-1) |
| BR112019014187A2 (pt) | 2017-01-09 | 2020-02-11 | Tesaro, Inc. | Métodos de tratamento de câncer com anticorpos anti-pd-1 |
| JP2020520921A (ja) | 2017-05-18 | 2020-07-16 | テサロ， インコーポレイテッド | 癌を処置する併用療法 |
| EP3687505A1 (fr) | 2017-09-26 | 2020-08-05 | Tesaro Inc. | Formulations de niraparib |
| SG11202002862RA (en) | 2017-09-30 | 2020-04-29 | Tesaro Inc | Combination therapies for treating cancer |
| MX2020003799A (es) | 2017-10-06 | 2020-11-06 | Tesaro Inc | Terapias de combinacion y usos de las mismas. |
| TW202024638A (zh) * | 2018-09-04 | 2020-07-01 | 美商泰沙羅公司 | 治療癌症之方法 |
| EP3860988A1 (fr) | 2018-10-03 | 2021-08-11 | Tesaro, Inc. | Formes cristallines d'une base libre de niraparib |
| TW202028181A (zh) | 2018-10-03 | 2020-08-01 | 美商提薩羅有限公司 | 尼拉帕尼（niraparib）鹽 |
| WO2020128908A2 (fr) * | 2018-12-20 | 2020-06-25 | Medimmune, Llc | Procédés de sélection et d'expansion de lymphocytes t exprimant pd-1 |
| WO2020243338A1 (fr) * | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Méthodes de traitement du cancer avec une protéine de fusion sirpalpha-fc en association avec un inhibiteur de point de contrôle immunitaire |
| KR20220129548A (ko) | 2019-12-18 | 2022-09-23 | 테사로, 인코포레이티드 | 생물제약 조성물 및 관련 방법 |
| WO2021136523A1 (fr) * | 2019-12-31 | 2021-07-08 | 甫康（上海）健康科技有限责任公司 | Combinaison pharmaceutique destinée à traiter des tumeurs et son application |
| WO2021152495A1 (fr) | 2020-01-28 | 2021-08-05 | Glaxosmithkline Intellectual Property Development Limited | Traitements combinés et utilisations et méthodes associées |
| US20230038044A1 (en) * | 2020-02-18 | 2023-02-09 | Innobation Bio Co., Ltd. | Companion diagnosis biomarker composition and companion diagnosis kit containing same |
| WO2021257124A1 (fr) * | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Traitement avec des anticorps anti-tigit et des antagonistes de liaison à l'axe pd-1 |
| WO2022025482A1 (fr) * | 2020-07-29 | 2022-02-03 | 재단법인 아산사회복지재단 | Composition pour la prévention et le traitement du cancer colorectal, comprenant de la streptonigrine et un inhibiteur de point de contrôle immunitaire en tant que principes actifs |
| WO2023076668A1 (fr) * | 2021-10-29 | 2023-05-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions et méthodes de traitement du cancer |
| WO2023153763A1 (fr) * | 2022-02-08 | 2023-08-17 | 고려대학교 산학협력단 | Vaccin contre le cancer comprenant un épitope de c-met et un épitope de hif1alpha, et son utilisation |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| WO1994028143A1 (fr) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Genes de fusion selectables et bifonctionnels se basant sur le gene de cytosine-deaminase (cd) |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| CA2414331C (fr) | 2000-06-28 | 2011-11-29 | Genetics Institute, Llc. | Molecules pd-l2 : nouveaux ligands de pd-1 et utilisations de ceux-ci |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| JP3871326B2 (ja) | 2000-11-15 | 2007-01-24 | 小野薬品工業株式会社 | Ｐｄ−１欠損マウスおよびその用途 |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| CA2442066C (fr) | 2001-04-02 | 2005-11-01 | Wyeth | Le pd-1, recepteur du b7-4, et ses utilisations |
| WO2003011911A1 (fr) | 2001-07-31 | 2003-02-13 | Ono Pharmaceutical Co., Ltd. | Substance specifique pour pd-1 |
| WO2003042402A2 (fr) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents modulant l'activite de cellules immunes et procedes d'utilisation associes |
| EP3287144A1 (fr) | 2002-07-03 | 2018-02-28 | ONO Pharmaceutical Co., Ltd. | Compositions immunostimulantes |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| ES2729974T3 (es) | 2003-01-23 | 2019-11-07 | Ono Pharmaceutical Co | Anticuerpo específico de PD-1 y CD3 humanas |
| CA2970873C (fr) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies |
| SI1907000T2 (sl) | 2005-06-08 | 2020-07-31 | Dana-Farber Cancer Institute | Postopki in sestavki za zdravljenje persistentne HIV infekcije z inhibicijo programiranih celični smrtnih 1 (PD-1) poti |
| ES2547463T3 (es) | 2005-06-17 | 2015-10-06 | Merck Sharp & Dohme Corp. | Moléculas de unión a ILT3 y usos de las mismas |
| WO2007100098A1 (fr) | 2006-03-03 | 2007-09-07 | Kyoto University | Multimere de domaine extracellulaire d'une molecule fonctionnelle de surface cellulaire |
| KR20150002879A (ko) * | 2006-10-02 | 2015-01-07 | 에이씨 이뮨 에스.에이. | 아밀로이드 베타에 대해 인간화된 항체 |
| EP2133365B1 (fr) | 2006-12-27 | 2017-05-17 | Emory University | Compositions et procédés pour le traitement d'infections et de tumeurs |
| EP2109608B1 (fr) | 2007-01-10 | 2011-03-23 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Indazoles à substitution amide utilisés comme inhibiteurs de la poly(adp-ribose)polymérase (parp) |
| US8603950B2 (en) | 2007-02-20 | 2013-12-10 | Anaptysbio, Inc. | Methods of generating libraries and uses thereof |
| MY149129A (en) | 2007-03-20 | 2013-07-15 | Lilly Co Eli | Anti-sclerostin antibodies |
| WO2008147143A2 (fr) | 2007-05-30 | 2008-12-04 | Postech Academy-Industry Foundation | Protéines de fusion d'immunoglobuline |
| EP3222634A1 (fr) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Anticorps dirigés contre le récepteur humain de mort programmée pd-1 |
| WO2009014708A2 (fr) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Anticorps pd-1 en combinaison avec une cellule sécrétant de la cytokine et leurs procédés d'utilisation |
| WO2009026472A1 (fr) | 2007-08-21 | 2009-02-26 | The General Hospital Corporation | Procédés pour induire une tolérance |
| US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
| CN106008460B (zh) | 2008-01-08 | 2022-08-12 | 默沙东公司 | 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐 |
| EP2262837A4 (fr) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
| EP2307050A4 (fr) | 2008-07-04 | 2012-07-25 | Ono Pharmaceutical Co | Utilisation d un marqueur d efficacité destiné à optimiser l efficacité thérapeutique d un anticorps pd-1 anti-humain sur les cancers |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010027423A2 (fr) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions d'antagonistes de pd-1 et methodes d'utilisation associees |
| US9181342B2 (en) | 2008-09-12 | 2015-11-10 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| CA2736829C (fr) | 2008-09-12 | 2018-02-27 | Isis Innovation Limited | Anticorps specifiques de pd-1 et leurs utilisations |
| AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| MX2011005691A (es) | 2008-11-28 | 2011-07-20 | Univ Emory | Metodos para el tratamiento de infecciones y tumores. |
| WO2010089411A2 (fr) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Anticorps pd-1 et anticorps pd-l1 et leurs utilisations |
| MY162511A (en) * | 2009-11-04 | 2017-06-15 | Merck Sharp & Dohme | Engineered anti-tslp antibody |
| SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| CA2791930A1 (fr) | 2010-03-11 | 2011-09-15 | Kerry Louise Tyson | Anticorps pd-1 |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| AU2011227335B2 (en) * | 2010-03-17 | 2014-11-06 | Abbott Research B.V. | Anti-nerve growth factor (NGF) antibody compositions |
| US20130035472A1 (en) | 2010-03-17 | 2013-02-07 | Anaptysbio, Inc. | Method of producing transcripts using cryptic splice sites |
| WO2011159877A2 (fr) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Anticorps di-spécifiques anti-tim-3 et pd-1 pour immunothérapie dans des états pathologiques immuns chroniques |
| JP2013541937A (ja) | 2010-08-05 | 2013-11-21 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ｍｈｃ抗体−抗ウイルス性サイトカイン融合タンパク質 |
| US20130217656A1 (en) | 2010-08-12 | 2013-08-22 | Beth Israel Deaconess Medical Center Inc | Methods and compositions for diagnosing and treating lupus |
| US20130310266A1 (en) | 2010-09-03 | 2013-11-21 | Immport Therapeutics, Inc. | Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders |
| EP2910572B1 (fr) | 2010-11-11 | 2017-09-06 | Versitech Limited | Variants solubles pd-1, structures de fusion et utilisations de ceux-ci |
| CN103561771B (zh) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
| TR201810298T4 (tr) | 2011-03-31 | 2018-08-27 | Merck Sharp & Dohme | İnsan programlı ölüm reseptörü PD-1'e karşı antikorların stabil formülasyonları ve ilgili tedaviler. |
| US8609625B2 (en) | 2011-06-24 | 2013-12-17 | Taipei Veterans General Hospital | Method for enhancing immune response in the treatment of infectious and malignant diseases |
| ES2893855T3 (es) | 2011-08-11 | 2022-02-10 | Ono Pharmaceutical Co | Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1 |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2013169693A1 (fr) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Méthodes destinées à traiter le cancer à l'aide d'un polypeptide il-21 et d'un anticorps anti-pd-1 |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US20150079192A1 (en) | 2012-05-21 | 2015-03-19 | Marv Enterprises, LLC | Treatment of cancer by manipulating the immune system |
| WO2013174997A1 (fr) | 2012-05-25 | 2013-11-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement de malignités hématologiques réfractaires |
| MY186099A (en) | 2012-05-31 | 2021-06-22 | Genentech Inc | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| EP2992017B1 (fr) * | 2013-05-02 | 2020-11-18 | AnaptysBio, Inc. | Anticorps dirigés contre la protéine de mort programmée 1 (pd-1) |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| WO2015134605A1 (fr) * | 2014-03-05 | 2015-09-11 | Bristol-Myers Squibb Company | Traitement du cancer du rein à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un autre agent anticancéreux |
| ME03558B (fr) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molécules d'anticorps anti-lag-3 et leurs utilisations |
| CN107172880B (zh) | 2014-03-24 | 2021-09-28 | 癌症研究技术有限公司 | 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途 |
| LT3157956T (lt) | 2014-06-19 | 2020-05-11 | Regeneron Pharmaceuticals, Inc. | Nepriklausantys žmonėms gyvūnai, turintys humanizuotą užprogramuotos ląstelių žūties 1 geną |
| ES2847311T3 (es) | 2014-08-05 | 2021-08-02 | MabQuest SA | Reactivos inmunológicos que se unen a PD-1 |
| WO2016029073A2 (fr) * | 2014-08-22 | 2016-02-25 | Bristol-Myers Squibb Company | Traitement du cancer à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un anticorps anti-cd137 |
| AU2015327868A1 (en) | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
| WO2016070051A2 (fr) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Thérapie combinée pour le traitement d'une maladie |
| WO2016100882A1 (fr) | 2014-12-19 | 2016-06-23 | Novartis Ag | Polythérapies |
| MA41217A (fr) | 2014-12-19 | 2017-10-24 | Advaxis Inc | Polythérapies ayant des souches de listeria recombinées |
| EP3916017A1 (fr) | 2014-12-22 | 2021-12-01 | PD-1 Acquisition Group, LLC | Anticorps anti-pd-1 |
| NZ734144A (en) | 2014-12-31 | 2023-06-30 | Checkmate Pharmaceuticals Inc | Combination tumor immunotherapy |
| US20170152323A1 (en) | 2015-01-16 | 2017-06-01 | Immunwork Inc. | Anti-inflammatory molecules with tissue-targeting functions |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
| HUE050894T2 (hu) * | 2015-04-17 | 2021-01-28 | Bristol Myers Squibb Co | Kompozíciók, amelyek tartalmazzák ipilimumab és nivolumab kombinációját |
| KR20170140316A (ko) * | 2015-04-28 | 2017-12-20 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체를 사용한 pd-l1-양성 흑색종의 치료 |
| SI3317301T1 (sl) | 2015-07-29 | 2021-10-29 | Novartis Ag | Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3 |
| EP4302835A3 (fr) | 2016-06-29 | 2024-03-20 | Tesaro, Inc. | Méthodes de traitement du cancer de l'ovaire |
| AU2017354070A1 (en) * | 2016-11-01 | 2019-05-16 | Anaptysbio, Inc. | Antibodies directed against programmed death- 1 (PD-1) |
| TW201825512A (zh) * | 2016-11-29 | 2018-07-16 | 美商提薩羅有限公司 | 針對計劃性死亡-１（ｐｄ-１）之抗體 |
| CA3049536A1 (fr) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methodes de traitement du cancer au moyen d'anticorps anti-tim-3 |
| BR112019014187A2 (pt) | 2017-01-09 | 2020-02-11 | Tesaro, Inc. | Métodos de tratamento de câncer com anticorpos anti-pd-1 |
| SG11202002862RA (en) | 2017-09-30 | 2020-04-29 | Tesaro Inc | Combination therapies for treating cancer |
-
2018
- 2018-01-09 BR BR112019014187-1A patent/BR112019014187A2/pt unknown
- 2018-01-09 MX MX2019008207A patent/MX2019008207A/es unknown
- 2018-01-09 AU AU2018206481A patent/AU2018206481A1/en active Pending
- 2018-01-09 DK DK18704101.7T patent/DK3565844T3/da active
- 2018-01-09 CN CN201880016132.XA patent/CN110382545A/zh active Pending
- 2018-01-09 TW TW107100822A patent/TWI767976B/zh active
- 2018-01-09 HU HUE18704101A patent/HUE061842T2/hu unknown
- 2018-01-09 CA CA3049440A patent/CA3049440A1/fr active Pending
- 2018-01-09 SG SG11201906192SA patent/SG11201906192SA/en unknown
- 2018-01-09 US US16/476,536 patent/US11407830B2/en active Active
- 2018-01-09 SG SG10201913075RA patent/SG10201913075RA/en unknown
- 2018-01-09 JP JP2019537103A patent/JP7110206B6/ja active Active
- 2018-01-09 KR KR1020197023407A patent/KR102606252B1/ko active IP Right Grant
- 2018-01-09 FI FIEP18704101.7T patent/FI3565844T3/fi active
- 2018-01-09 EP EP18704101.7A patent/EP3565844B8/fr active Active
- 2018-01-09 PL PL18704101.7T patent/PL3565844T3/pl unknown
- 2018-01-09 PT PT187041017T patent/PT3565844T/pt unknown
- 2018-01-09 EP EP23158731.2A patent/EP4219563A3/fr active Pending
- 2018-01-09 WO PCT/US2018/013029 patent/WO2018129559A1/fr unknown
- 2018-01-09 MA MA047208A patent/MA47208A/fr unknown
- 2018-01-09 ES ES18704101T patent/ES2945745T3/es active Active
-
2019
- 2019-06-28 ZA ZA2019/04316A patent/ZA201904316B/en unknown
- 2019-07-02 IL IL267804A patent/IL267804A/en unknown
-
2022
- 2022-04-11 JP JP2022065095A patent/JP2022082809A/ja active Pending
- 2022-07-15 US US17/812,933 patent/US20230111418A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA47208A (fr) | 2019-11-13 |
| BR112019014187A2 (pt) | 2020-02-11 |
| US11407830B2 (en) | 2022-08-09 |
| HUE061842T2 (hu) | 2023-08-28 |
| EP4219563A2 (fr) | 2023-08-02 |
| EP4219563A3 (fr) | 2023-10-04 |
| AU2018206481A1 (en) | 2019-07-25 |
| IL267804A (en) | 2019-09-26 |
| KR20190114996A (ko) | 2019-10-10 |
| PT3565844T (pt) | 2023-05-02 |
| EP3565844B1 (fr) | 2023-03-01 |
| KR102606252B1 (ko) | 2023-11-23 |
| JP7110206B2 (ja) | 2022-08-01 |
| JP7110206B6 (ja) | 2022-08-25 |
| ES2945745T3 (es) | 2023-07-06 |
| EP3565844B8 (fr) | 2023-04-12 |
| PL3565844T3 (pl) | 2023-06-12 |
| EP3565844A1 (fr) | 2019-11-13 |
| ZA201904316B (en) | 2022-12-21 |
| MX2019008207A (es) | 2019-12-11 |
| DK3565844T3 (da) | 2023-05-01 |
| WO2018129559A1 (fr) | 2018-07-12 |
| FI3565844T3 (fi) | 2023-05-09 |
| JP2022082809A (ja) | 2022-06-02 |
| CA3049440A1 (fr) | 2018-07-12 |
| US20200239574A1 (en) | 2020-07-30 |
| CN110382545A (zh) | 2019-10-25 |
| TW201831200A (zh) | 2018-09-01 |
| JP2020504141A (ja) | 2020-02-06 |
| US20230111418A1 (en) | 2023-04-13 |
| TWI767976B (zh) | 2022-06-21 |
| SG11201906192SA (en) | 2019-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267804A (en) | Methods for treating cancer with anti-pd-1 antibodies | |
| IL267803A (en) | Methods for treating cancer with anti-tim-3 antibodies | |
| HK1252272A1 (zh) | 使用抗ox40抗體治療癌症的方法 | |
| HK1245134A1 (zh) | 用抗lap單克隆抗體治療癌症 | |
| IL275663A (en) | Cancer treatment methods | |
| HK1258098A1 (zh) | 治療癌症的方法 | |
| IL262562A (en) | Combination of anti-pd-1 antibodies and radiation for cancer therapy | |
| IL263925A (en) | Methods of treating ovarian cancer | |
| IL265541B1 (en) | Bispecific antibodies and compounds containing them for the treatment of cancer | |
| IL264674B1 (en) | Antibodies to siglec7 for cancer treatment | |
| IL276303A (en) | Methods of treating cancer with ANTI-PD-1 antibodies | |
| IL268479A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
| IL266990A (en) | Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens | |
| ZA202005223B (en) | Methods of treating cancers with antagonistic anti-pd-1 antibodies | |
| IL273196A (en) | Claudin 6 antibodies and methods of cancer treatment | |
| IL262342A (en) | Cancer treatment methods | |
| EP3645040A4 (fr) | Utilisation d'anticorps anti-fam19a5 pour le traitement de cancers | |
| IL268460A (en) | Treatment of bladder cancer with an antibody against pd-l1 | |
| SG11202005163PA (en) | Methods of treating cancer | |
| IL269123A (en) | Methods of treating cancer |